Interdict Bio
PrivateMomentum
Top 50%
of companies Caplight tracks
Company Overview
Interdict Bio is a biotechnology company that develops small molecule therapeutics targeting historically undruggable proteins in oncology, rare diseases, neurodegeneration, and autoimmunity.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Interdict Bio Comparables
Compare Interdict Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Initial Therapeutics | 89% | |
| Arrakis Therapeutics | 77% | |
| Anima Biotech | 76% |
Interdict Bio Funding Rounds
Historical fundraising activity
Key People
Founding team and executive leadership
Interdict Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Altitude Life Science Ventures | Seed |
| Venrock | Seed |
| Mission Bay Capital | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 924% MoM.
- Jan 21, 2026
Monthly visitors increased by 50% MoM.
Interdict Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access